GlobeNewswire Inc.··SanofiSanofi's Nuvaxovid Shows Superior Safety Profile Against Moderna's mRNA Vaccine
Sanofi's protein-based COVID-19 vaccine demonstrated significantly lower side effects than Moderna's mNEXSPIKE in head-to-head trial of 1,000 adults.
SNYMRNAclinical trialCOVID-19 vaccine